Lamprene (clofazimine) / Novartis - LARVOL DELTA

Temporal trends in treatment strategies and outcomes of newly diagnosed Mycobacterium avium complex pulmonary disease. (PubMed, Int J Tuberc Lung Dis) - "While the use of rifampicin declined, the use of azithromycin, inhaled or intravenous amikacin, and clofazimine increased over time. The probability of culture conversion progressively improved (Tarone-Ware test, P CONCLUSIONSince 2011, treatment strategies for MAC-PD have evolved toward a more proactive approach, accompanied by a gradual improvement in treatment outcomes.."

Journal • Retrospective data • Pulmonary Disease • Respiratory Diseases

Emergence of Rv0678 (mmpR5) Mutations Mediating Resistance to Bedaquiline and Clofazimine in a Liver Transplant Recipient with Rifampicin-Susceptible Tuberculosis: A Case Report. (PubMed, Int J Infect Dis) - "Phenotypic drug susceptibility testing (DST) further confirmed susceptibility to Bdq and Cfz before Bdq exposure and resistance to both drugs after Bdq treatment. This case highlights the critical need for potent combination regimens during Bdq treatment, particularly among immunocompromised patients."

Journal • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Transplantation • Tuberculosis

Enhanced In Vitro Stability of Bedaquiline with Ascorbic Acid and Pyruvate During Long-Term Incubation in Mycobacterium Species. (PubMed, Antibiotics (Basel)) - "These findings suggest that the combined use of AA and P may serve as an effective stabilizing strategy for BDQ during MIC determination."

Journal • Preclinical • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Wild-type MIC distribution and evaluation of epidemiological cut-offs of second-line TB-drugs in susceptible and MDR-TB clinical isolates from Chennai, India. (PubMed, Front Microbiol) - "Building on these findings, the present study systematically evaluated the epidemiological cut-off values and pharmacodynamic profiles of newer and repurposed second-line anti-TB drugs - Bedaquiline, Delamanid, Moxifloxacin, Linezolid, Clofazimine, Levofloxacin, and Pretomanid against the first-line drug-sensitive and isolates that are resistant to Rifampicin and Isoniazid from tuberculosis patients in and around Chennai. Concordantly, pharmacodynamic analyses revealed sub-therapeutic exposure ranges for several newer and repurposed anti-TB drugs, underscoring the potential for treatment failure even in strains classified as susceptible. Collectively, these findings highlight the urgent need for regionally calibrated epidemiological cut-off values to optimize drug dosing, improve MDR-TB treatment outcomes, and strengthen resistance surveillance frameworks."

Journal • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

MYCOBACTERIUM ABSCESSUS AS A COMPLICATION OF IMMUNOSUPPRESSION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR CONGENITAL NEUTROPENIA (EBMT 2026) - "Despite treatment with systemic corticosteroids, ruxolitinib, ibrutinib, antiviral agents, and antifungal therapy for a probable invasive pulmonary aspergillosis infection, respiratory status continued to decline.By day +190, the patient presented with septic shock, for which invasive mechanical ventilation (IMV), fluid expansion and vasopressor therapy were required...BAL and blood cultures were positive for M. abscessus massiliense, confirming invasive pulmonary disease with bacteremia.Treatment consisted of intravenous amikacin, tigecycline, imipenem, and TDM guided azithromycin and clofazimine, in addition to ongoing antifungal therapy... This case illustrates how Mabs can emerge insidiously in pediatric alloSCT recipients, mimicking more common post-transplant complications and progressing rapidly to severe invasive infection. The patient's gradual recovery underscores the importance of early recognition, aggressive multidrug therapy, and careful reassessment of..."

Graft versus Host Disease • Hematological Disorders • Hepatology • Immunology • Infectious Disease • Inflammation • Neutropenia • Nontuberculous Mycobacterial Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases • Septic Shock • Transplantation • CSF3R

SUCCESSFUL TREATMENT WITH CLOFAZIMINE FOR MACROLIDE-RESISTANT MYCOBACTERIUM ABSCESSUS INFECTION IN A PERITONEAL DIALYSIS PATIENT (ISN-WCN 2026) - "The patient transitioned to hemodialysis following catheter removal 11 days after symptom onset, with extensive surgical debridement and a 6-week combination antibiotic therapy including imipenem-cilastatin, amikacin and clarithromycin, achieving clinical cure. However, the infection recurred after 5 months, necessitating retreatment with debridement and an antibiotic regimen including imipenem-cilastatin, amikacin, azithromycin and clofazimine for 4 weeks, followed by a continuation regimen with amikacin, clofazimine and sitafloxacin for 4 months...Our case represents the first successful treatment of macrolide-resistant M. abscessus PD-associated infection using clofazimine-containing combination therapy, demonstrating clofazimine as a potential therapeutic option in combination therapy. Multimodal therapy including early catheter removal, extensive surgical debridement, and prolonged multidrug antimicrobial regimens containing clofazimine may represent a viable..."

Clinical • Autosomal Dominant Polycystic Kidney Disease • Genetic Disorders • Infectious Disease • Nephrology • Nontuberculous Mycobacterial Disease • Polycystic Kidney Disease • Renal Disease • Respiratory Diseases • Tuberculosis • CRP

CATHETER-RELATED INFECTION CAUSED BY NON-TUBERCULOUS MYCOBACTERIUM IN A PERITONEAL DIALYSIS PATIENT (ISN-WCN 2026) - "She was treated with cefoxitin, amikacin and azithromycin induction therapy for 3 weeks and subsequently maintained on azithromycin and clofazimine, which were later stopped in mid Sep 2024 as she developed liver impairment and had good clinical improvement with no discharge noted from the old right exit site and right paramedian incision wounds. She was treated with 1 month of induction combination therapy followed by six months of maintenance therapy till May 2025. She remained on HD initially and returned to PD in April 2025.Conclusion This case highlights the need for a prolonged course of maintenance antibiotic therapy to effectively treat Mycobacterium abscessus catheter-related infection, as inadequate treatment duration may lead to recurrence."

Clinical • Cardiovascular • Chronic Kidney Disease • Dyslipidemia • Endocrine Disorders • Glomerulonephritis • Hypertension • Infectious Disease • Nontuberculous Mycobacterial Disease • Renal Disease • Respiratory Diseases

A CASE OF LUPUS ENCEPHALOPATHY COMPLIATED WITH TUBERCULOUS MENINGITIS TREATED WITH TELITACICEPT (ISN-WCN 2026) - "The treatment regimen was adjusted to "isoniazid, rifabutin, pyrazinamide, ethambutol, and clofazimine" for intensive anti - tuberculosis treatment. This case can provide a reference for similar clinical cases. In the future, more large - scale, multi - center clinical studies are needed to comprehensively evaluate its long - term efficacy and safety, providing a basis for its widespread application."

Clinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Epilepsy • Glomerulonephritis • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Lupus Nephritis • Musculoskeletal Diseases • Musculoskeletal Pain • Nephrology • Orthopedics • Respiratory Diseases • Systemic Lupus Erythematosus • Tuberculosis

Clinical Characteristics and Drug Resistance Profile of Mycobacterium colombiense Infection: A Study of 22 Cases. (PubMed, Infect Drug Resist) - "Drug susceptibility testing performed in 11 cases revealed high sensitivity to bedaquiline, clofazimine, rifabutin, ethambutol, and rifampin. Timely therapeutic intervention can improve patient prognosis to some extent. This study offers valuable references for the clinical diagnosis and treatment of Mycobacterium colombiense infection, underscoring its practical significance in clinical practice."

Journal • Cough • Fatigue • Human Immunodeficiency Virus • Infectious Disease • Musculoskeletal Pain • Nontuberculous Mycobacterial Disease • Pain • Respiratory Diseases

Patterns of Drug Resistance and Treatment Outcomes in Drug-Resistant Tuberculosis Patients in Fuyang City: A Three-Year Retrospective Study. (PubMed, Infect Drug Resist) - "Ethambutol showed the highest resistance prevalence (69.61%), followed by isoniazid (64.64%), rifampicin (51.38%), and streptomycin (33.70%)...Annual increases were observed in the use of cycloserine, bedaquiline, linezolid, and clofazimine (p < 0.05)...DR-TB remains a significant burden in Fuyang City, with high first-line drug resistance rates, a high proportion of MDR-TB exhibiting complex resistance profiles, and suboptimal treatment success. Bedaquiline-containing regimens are protective against poor outcomes."

Journal • Retrospective data • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Antibacterial activity of clofazimine and bedaquiline and mutations associated with resistance in the Mycobacterium avium complex and Mycobacterium abscessus complex (ESCMID Global 2026) - No abstract available

Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Clofazimine use for non-tuberculous mycobacterial infections: ten-year experience in Belgium (ESCMID Global 2026) - No abstract available

Nontuberculous mycobacteria • Infectious Disease • Nontuberculous Mycobacterial Disease • Respiratory Diseases

Metabolic shutdown of Mycobacterium avium in response to clofazimine and macrolide antibiotics (ESCMID Global 2026) - No abstract available

Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Acquisition of bedaquiline and clofazimine resistance in association with a novel loss-of-function mutation in the pepQ gene during treatment of multidrug-resistant tuberculosis. (PubMed, ASM Case Rep) - "Bedaquiline (BDQ) has transformed the management of multidrug-resistant (MDR) and rifampin-resistant tuberculosis (TB)...Therapeutic drug monitoring while on MDR therapy (daily ethambutol, pyrazinamide, linezolid, CFZ, and intravenous amikacin) detected low serum levels of CFZ, which was not addressed prior to the addition of BDQ to her 5-drug regimen and may have selected for BDQ/CFZ cross-resistance. This case contributes to the limited clinical data implicating pepQ in BDQ/CFZ cross-resistance and describes a novel loss-of-function mutation associated with resistance. As our understanding of genotypic BDQ resistance remains elementary, when novel drug mutations arise, practitioners should consider their significance in the context of phenotypic drug susceptibility test results and the patient's clinical response."

Journal • Crohn's disease • Gastroenterology • Immunology • Infectious Disease • Inflammatory Bowel Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Late-Onset Acute Cellular Rejection after Lung Transplantation Triggered by a Fluctuation in the Tacrolimus Trough Level Which Was Successfully Treated with Steroid Pulse Therapy. (PubMed, Intern Med) - "Onset followed azithromycin and clofazimine for Mycobacterium abscessus, which caused the tacrolimus trough levels to drop. Although C4d staining was positive, the absence of donor-specific antibodies and histological findings supported the diagnosis of ACR. This case highlights the need for careful monitoring of tacrolimus trough levels and a comprehensive diagnostic workup to ensure the timely and appropriate treatment of late-onset rejection."

Journal • Antibody-mediated Rejection • Pulmonary Disease • Transplantation

FORMaT-EVOLVE: Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (clinicaltrials.gov) - P2 | N=300 | Not yet recruiting | Sponsor: The University of Queensland

New P2 trial • Cystic Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Nontuberculous Mycobacterial Disease • Pulmonary Disease • Respiratory Diseases

Real-world experience of prolonged treatment for treatment-refractory nontuberculous mycobacterial pulmonary disease: Benefits and harms of extending therapy beyond 24 months. (PubMed, Respiration) - "Extending antibiotic therapy beyond 24 months in patients with treatment-refractory NTM-PD does not necessarily confer additional microbiological, radiographic, or survival benefits, and may increase the risk of adverse events. Therefore, prolonged therapy should be reserved for selected patients, with close monitoring for side effects and macrolide resistance."

Journal • Real-world evidence • Hematological Disorders • Immunology • Infectious Disease • Nontuberculous Mycobacterial Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Outcomes of alternative therapy in HLA-B* 13:01 positive leprosy patients without dapsone versus standard MDT in negative patients: A comparative effectiveness study. (PubMed, PLoS Negl Trop Dis) - "In our study, dapsone-free alternative regimens demonstrated comparable clinical efficacy and safety to standard MDT in MB patients, providing a viable option for HLA-B*13:01 carriers. These findings, limited by the observational design and regimen heterogeneity, warrant further investigation in prospective trials."

HEOR • Journal • Immunology • HLA-B

Effectiveness and safety of a shortened oral regimen for rifampicin- or multidrug-resistant TB. (PubMed, IJTLD Open) - "This 9-month oral regimen was effective and safe and improved patient-reported outcomes. These results support broader adoption in national TB programmes across Latin America and beyond."

Journal • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Innovating shorter, all-oral, precise, individualized treatment regimen for rifampicin-resistant tuberculosis (INSPIRE TB): study protocol for a pragmatic randomised controlled trial. (PubMed, BMC Infect Dis) - P3 | "Identifying safer and effective short regimens remains an obstacle for drug-resistant tuberculosis and more treatment options are needed to benefit patients from different countries and settings to reduce disease burden. The INSPIRE TB study hopes to provide robust evidence on various options of safer and effective 9-month oral regimens for RR-TB in China."

Journal • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Successful treatment with clofazimine for macrolide-resistant Mycobacterium abscessus infection in a peritoneal dialysis patient: A case report and literature review. (PubMed, Perit Dial Int) - "Initial management included early catheter removal, extensive surgical debridement, and 6 weeks of combination antibiotic therapy, including imipenem-cilastatin, amikacin, and clarithromycin, achieving clinical cure. However, the infection recurred after 5 months, necessitating retreatment with debridement and an antibiotic regimen including imipenem-cilastatin, amikacin, azithromycin, and clofazimine for 4 weeks, followed by a continuation regimen with amikacin, clofazimine, and sitafloxacin for 4 months...Based on a literature review of 67 cases of M. abscessus PD-associated infections, all six cases treated with clofazimine achieved clinical cure, but there were no reports on cases of macrolide-resistant M. abscessus treated with clofazimine. Our case represents the first successful clofazimine treatment of macrolide-resistant M. abscessus PD-associated infection, demonstrating clofazimine as a potentially effective oral antibiotic option in combination therapy,..."

Journal • Infectious Disease • Inflammation • Nontuberculous Mycobacterial Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Unveiling Lepromatous Leprosy in a Non-endemic Region: A Case of Delayed Diagnosis and Effective ROM (Rifampin, Ofloxacin, and Minocycline) Therapy. (PubMed, Cureus) - "ROM therapy demonstrated a favorable treatment outcome, presenting a well-tolerated alternative to the World Health Organization's standard MDT regimen with rifampin, dapsone, and clofazimine. Clinicians should maintain a high index of suspicion for leprosy in patients with chronic, non-healing skin lesions, particularly when there is a history of travel to endemic regions, even many years prior. Further research comparing ROM and MDT regimens is warranted."

Journal • Dermatology • Infectious Disease

Rifampicin-resistant tuberculosis in Spain. (PubMed, ERJ Open Res) - "Treatment included bedaquiline in 39 (41.5%) patients, linezolid in 87 (92.6%), fluoroquinolones in 82 (87.2%), clofazimine in 64 (68.0%) and delamanid in 27 (28.7%). Most patients achieved successful outcomes with individualised regimens guided predominantly by experts. Patients with pre-XDR-TB and those with comprehension difficulties had significantly reduced success rates."

Journal • Human Immunodeficiency Virus • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

PRESCIENT: Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB (clinicaltrials.gov) - P2 | N=94 | Active, not recruiting | Sponsor: Brigham and Women's Hospital | N=156 ➔ 94

Enrollment change • Human Immunodeficiency Virus • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis • CD4

Bilateral Orthotopic Lung Transplantation in a Patient with Mycobacterium Abscessus and Mycobacterium Avium Intracellulare Pneumonia (ISHLT 2026) - "The patient was diagnosed with M. abscessus massiliense with a non-functional erm gene six years prior and had undergone treatment with ceftaroline, tigecycline, and imipenem-cilastin which was escalated to intravenous amikacin, azithromycin, and tigecycline and enteric ethambutol and rifabutin. Nucleic acid amplification testing and acid-fast bacilli culture from repeat bronchoalveolar lavage were positive for M. abscessus massiliense and MAI and she failed to improve despite initiation of linezolid, amikacin, tigecycline, rifabutin, azithromycin, and ethambutol. The patient underwent BOLT, fully recovered, and was discharged 22 days following BOLT on enteric linezolid, bedaquiline, tigecycline, and azithromycin and inhaled amikacin and clofazimine which were well tolerated.Summary Despite challenges with eradication, lung transplantation should be considered in patients with advanced lung disease and M. abscessus infection."

Clinical • Acute Respiratory Distress Syndrome • Cystic Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Pneumonia • Transplantation